<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128115</url>
  </required_header>
  <id_info>
    <org_study_id>0677-032</org_study_id>
    <secondary_id>2005_028</secondary_id>
    <nct_id>NCT00128115</nct_id>
  </id_info>
  <brief_title>Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)</brief_title>
  <official_title>Proprietary Information - Exploratory (Non-Confirmatory) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate an improvement in physical functional recovery,&#xD;
      following administration of Drug for 24 weeks, in patients who have recently experienced a&#xD;
      hip fracture. This study will also evaluate the safety and tolerability of Drug.&#xD;
&#xD;
      This is an early phase trial and some specific protocol information is proprietary and not&#xD;
      publicly available at this time. (Full information is available to trial participants).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proprietary Information - Exploratory (Non-Confirmatory) Trial</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proprietary Information - Exploratory (Non-Confirmatory) Trial</measure>
  </secondary_outcome>
  <enrollment type="Actual">83</enrollment>
  <condition>Hip Fracture</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0677</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has had surgery for a unilateral hip fracture, and is considered to be&#xD;
             partially or fully weight bearing after the surgery&#xD;
&#xD;
          -  Surgical repair of the fracture has occurred no more than 4 days post hip fracture&#xD;
&#xD;
          -  Prior to starting the study medication, the patient is enrolled in a rehabilitation&#xD;
             program (as an in-patient or as an out-patient)&#xD;
&#xD;
          -  Patient is judged to have been able to ambulate independently at home prior to their&#xD;
             hip fracture (able to walk indoors in a familiar setting with little or no aid from&#xD;
             another person)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has an unstable medical condition&#xD;
&#xD;
          -  Patient has a hip fracture that is due to bone pathology other than osteoporosis&#xD;
             (e.g., malignancy, or Paget's Disease), or major trauma (e.g. motor vehicle accident).&#xD;
&#xD;
          -  Patient has Type I diabetes&#xD;
&#xD;
          -  Patient has Type II diabetes with any of conditions;&#xD;
&#xD;
               1. Patient is currently taking more than one anti-hyperglycemic agent, or is taking&#xD;
                  a single combination anti-hyperglycemic drug containing more than one&#xD;
                  anti-hyperglycemic medication&#xD;
&#xD;
               2. Patient is currently receiving insulin. Note: A short-term course of insulin&#xD;
                  required for glycemic control post hip fracture surgery is not exclusionary&#xD;
&#xD;
               3. Patient has diabetic retinopathy&#xD;
&#xD;
               4. Patient is unwilling or unable to monitor glucose at home&#xD;
&#xD;
          -  Patient has been diagnosed with any neuromuscular or neurological disease causing&#xD;
             muscle weakness&#xD;
&#xD;
          -  Patient has cancer, or had a diagnosis of any malignancy within the last 5 years,&#xD;
             except for adequately treated basal cell or squamous cell skin cancer, or adequately&#xD;
             treated in situ cervical cancer&#xD;
&#xD;
          -  Patient has active carpal tunnel syndrome&#xD;
&#xD;
          -  Patient was living in a nursing home prior to the hip fracture (Note: - Patients who&#xD;
             were living in an assisted-living facility prior to the hip fracture are eligible for&#xD;
             enrollment)&#xD;
&#xD;
          -  Patient was permanently wheelchair bound prior to the hip fracture&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Msd Sharp &amp; Dohme Gmbh</name>
      <address>
        <city>Haar</city>
        <zip>85540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MSD (Norge) AS</name>
      <address>
        <city>Drammen</city>
        <zip>3011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme De Espana, S.A.E.</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (Sweden) AB</name>
      <address>
        <city>Sollentuna</city>
        <zip>192 07</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Merch Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <state>Hertfordshire</state>
        <zip>EN11 9BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Israel</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 5, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

